Study proposes reconsidering how histone deacetylase inhibitors work in cancer treatment

Article excerpt

Researchers at Baylor College of Medicine are upending decades of assumptions about how a widely used class of cancer drugs actually works. Histone deacetylase inhibitors have long been thought to function by blocking enzymes that fuel tumor growth. But new evidence suggests the mechanism may be fundamentally different from what scientists believed. The findings could reshape how these drugs are developed and used in cancer treatment, potentially unlocking more effective therapies or revealing why some patients don't respond to current approaches.